SynWeaveâ„¢: Revolutionizing Biopharma Manufacturing by Improving Titer, Timelines and Manufacturability
Since the establishment of Chinese Hamster Ovary (CHO) cells in the 1950s, the production of therapeutic proteins has seen continuous innovation and growth. The potential of therapeutic proteins, such as antibodies, bispecifics, antibody-drug conjugates (ADCs), and recombinant proteins, is driving the demand for high-titer clones.
Harnessing the Power of Upstream Platform Integration to Accelerate Biopharma Innovation
The biopharmaceutical industry has been a hotbed of innovation in recent years, with an increasing number of novel recombinant protein therapeutics receiving the U.S. Food and Drug Administration’s (FDA) green light.
The Future of Therapeutics: Syngene Leading the Charge with Targeted Protein Degradation Platform
In this exclusive interview Kenneth Barr, SVP of Discovery Research at Syngene International, sheds light on how Syngene is uniquely positioned to lead the targeted protein degradation revolution in drug discovery.
The $100 Billion Frontier: Untapped Potential in Animal Health Innovation
The global animal health market is a staggering $60 billion industry, projected to reach $100 billion by 2030. This phenomenal growth reflects a confluence of factors: rising pet ownership (especially companion animals), increasing protein demand, reducing gaseous emissions, and the ever-present threat of zoonotic diseases.
Advancing mAb manufacturing with customer-centric solutions
Monoclonal antibodies (mAbs) have become a cornerstone in modern therapeutics, offering targeted treatment options across various diseases, including cancer, autoimmune disorders, and infectious diseases.